OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen ® (rintatolimod), the Company’s investigational dsRNA and highly selective TLR3 agonist immunomodulator. Healthcare Business Today :...
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program OCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones Access it here OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept....
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom Latest milestone further strengthens AIM’s expanding global Ampligen patent estate across multiple therapeutic opportunities Follows newly issued U.S....
Patent covers synergistic use of Ampligen with pembrolizumab across cancer indications, including pancreatic, ovarian, colorectal, breast, lung and other cancers, reinforcing the potential breadth and long-term value of AIM’s oncology platform OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Video webcast now available here OCALA, Fla., Aug. 27, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it participated in the Virtual Investor “Why Now” on-demand conference....
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its potential application as a broad-spectrum prophylactic or early-onset antiviral countermeasure in Ebola and its variants Access the article...
Completed Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government-Funded Infectious Disease Initiatives in Ebola OCALA, Fla., Aug....
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...